EQ

Equillium Inc

1.37

Oct 30 • 3:59 PM ET -0.05 (-3.52%)

1.37

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: PALI IMUX ABVX PTGX SYRE CNTB ALMS KYMR RLYB ENTX

| Held by: VTI VXF IWC AVSC QQQS

Scroll to Statements

Index	-
Market Cap	86.87M
Enterprise Value	30.29M
Income	-18.01M
Sales	0.00M
Book/sh	0.88
Cash/sh	0.90
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Oct 12, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.55
P/C	1.52
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	23.40
Current Ratio	23.40
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.20
EPS next Y	-0.23
EPS next Q	-0.05
EPS this Y	47.44%
EPS next Y	-10.24%
EPS next 5Y	11.09%
EPS past 3/5Y	40.45% 23.22%
Sales past 3/5Y	- -
EPS Y/Y TTM	64.23%
Sales Y/Y TTM	-100.00%
EPS Q/Q	73.86%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	25.93% -

Insider Own	20.17%
Insider Trans	-3.08%
Inst Own	58.65%
Inst Trans	-3.13%
ROA	-50.68%
ROE	-58.98%
ROIC	-32.05%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.11%
SMA50	-22.42%
SMA200	-34.09%
Trades

Shs Outstand	63.41M
Shs Float	50.62M
Short Float	11.17%
Short Ratio	9.77
Short Interest	5.66M
52W High	3.54 -61.30%
52W Low	0.76 81.17%
Volatility	8.31% 9.92%
ATR (14)	0.13
RSI (14)	43.79
Beta	2.04
Rel Volume	0.54
Avg Volume	578.64K
Volume	310,727

Perf Week	11.38%
Perf Month	-11.04%
Perf Quarter	-37.73%
Perf Half Y	-34.13%
Perf YTD	-11.61%
Perf Year	-3.52%
Perf 3Y	158.83%
Perf 5Y	-78.29%
Perf 10Y	-
Recom	1.00
Target Price	8.60
Prev Close	1.42
Price	1.37
Change %	-3.52%

Consensus

Strong Buy

Avg. Price Target

$8.60

Implied Upside

+527.7%

Analysts10incl. previous ratings

Rating Distribution10 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 12, 2026	Resumed	LLeerink Partners	Outperform	$6	+338.0%
Jul 13, 2026	Initiated	PPiper Sandler	Overweight
May 28, 2026	Upgrade	LLeerink Partners	Market Perform → Outperform	$6	+338.0%
Apr 23, 2026	Initiated	OOppenheimer	Outperform	$7	+410.9%
Apr 16, 2026	Initiated	RB. Riley Securities	Buy	$6	+338.0%
Apr 14, 2026	Initiated	RRaymond James	Strong Buy	$6	+338.0%
Apr 07, 2026	Initiated	CCantor Fitzgerald	Overweight	$10	+629.9%
Mar 13, 2026	Initiated	RRoth Capital	Buy	$12	+775.9%
Feb 25, 2026	Initiated	SStifel	Buy	$5	+265.0%
Mar 28, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform	$3 → $1	-27.0%
Oct 29, 2021	Resumed	SStifel	Buy	$12	+775.9%
Sep 15, 2021	Initiated	CCantor Fitzgerald	Overweight	$14	+921.9%
Jul 14, 2020	Reiterated	HH.C. Wainwright	Buy	$14 → $24	+1,651.8%
Jul 10, 2020	Resumed	SStifel	Buy	$22 → $10	+629.9%
Feb 22, 2019	Initiated	SSVB Leerink	Outperform	$16	+1,067.9%

Oct-26-26 08:30AM	Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 (GlobeNewswire)
Oct-06-26 04:05PM	Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference (GlobeNewswire)
Oct-05-26 04:05PM	Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 (GlobeNewswire)
Sep-29-26 04:05PM	Equillium Announces Poster Presentations at the 7th International AHR Conference (GlobeNewswire)
Sep-16-26 08:30AM	Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum (GlobeNewswire) -9.51%
08:30AM	Loading…
Sep-02-26 08:30AM	Equillium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-26 04:05PM	Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) -7.80% +17.41%
Jun-02-26 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.42% +11.47%
May-28-26 04:05PM	Equillium to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) +7.98%
May-20-26 04:05PM	Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis (GlobeNewswire) +16.71% +7.28%
May-13-26 04:01PM	Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +12.12%
May-01-26 04:42PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-20-26 04:05PM	Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event (GlobeNewswire) +6.97%
Apr-08-26 08:30AM	Equillium Announces Poster Presentations at IMMUNOLOGY2026, the Annual Meeting of the American Association of Immunologists (GlobeNewswire) -6.25%
Apr-02-26 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Loading…
Mar-25-26 04:05PM	Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights (GlobeNewswire) +5.64%
Mar-18-26 08:30AM	Equillium to Participate in the 38th Annual Roth Conference (GlobeNewswire)
Mar-13-26 08:00AM	Equillium Announces $35 Million Financing with RA Capital Management (GlobeNewswire) +19.32%
Feb-25-26 08:30AM	Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
Feb-13-26 01:28PM	Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 Start (MarketBeat)
Feb-02-26 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.34%
Nov-20-25 04:35PM	Equillium to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:30AM	The Zacks Analyst Blog Highlights MS, VOO, SPY, IVV, SPYM, RSP, EQ and EQWL (Zacks)
Nov-13-25 04:05PM	Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update (GlobeNewswire) -9.09% +23.81%
Nov-04-25 08:30AM	Equillium to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.10%
Nov-03-25 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.93%
Oct-27-25 03:56AM	Cipla's flagship respiratory initiative Breathefree broadens its footprint in the UAE (PR Newswire)
Oct-22-25 08:00AM	Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 (GlobeNewswire) -6.52%
Oct-06-25 04:02PM	Equillium Announces Leadership and Corporate Updates (GlobeNewswire) +12.78%
Sep-03-25 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.72% -6.42%
07:30AM	Loading…
07:30AM	These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 (Motley Fool)
Aug-29-25 04:03PM	Equillium to Participate in the Cantor Global Healthcare Conference 2025 (Business Wire)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +78.88%
08:30AM	Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic (Business Wire)
Aug-04-25 08:30AM	Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy (Business Wire) -20.66%
Aug-01-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +81.59%
May-06-25 08:00AM	Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists (Business Wire) -8.15%
May-01-25 08:00AM	Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 (Business Wire)
Apr-24-25 09:00AM	Equillium Announces Feedback from the U.S. Food and Drug Administration (Business Wire)
Apr-01-25 09:55AM	Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks) +28.42%
Mar-27-25 12:49PM	Equillium pushes for breakthrough status despite missing primary endpoint (Clinical Trials Arena) -35.62%
07:00AM	Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights (Business Wire)
07:00AM	Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease (Business Wire)
Feb-21-25 09:55AM	Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Feb-10-25 12:00PM	Equillium (EQ) Upgraded to Buy: Here's What You Should Know (Zacks) -10.10%
08:50AM	Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Feb-06-25 04:18PM	Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge (GuruFocus.com) +33.03% -9.31%
08:00AM	Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis (Business Wire)
Nov-13-24 04:01PM	Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates (Business Wire) -8.18% -12.33%
08:00AM	Equillium to Present at the Stifel Healthcare Conference (Business Wire)
Nov-12-24 08:00AM	Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer (Business Wire) +13.24%
Nov-06-24 10:00AM	Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth (Zacks)
Oct-31-24 07:00AM	Equillium Maintains Rights to Itolizumab Following Ono Partnership (Business Wire) -37.61%
Oct-07-24 08:00AM	Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (Business Wire) +8.00%
Sep-17-24 11:54AM	Equillium collaborates with Vivtex for oral formulation of autoimmune therapy (Pharmaceutical Technology)
Sep-10-24 08:00AM	Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit (Business Wire)
Sep-04-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-28-24 08:00AM	Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference (Business Wire)
Aug-08-24 05:35PM	Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights (Business Wire)
Aug-06-24 08:00AM	Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease (Business Wire) +14.85%
Jul-18-24 01:57PM	Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance (Business Wire)
Jul-02-24 08:00AM	Equillium to Participate in Upcoming Investor Conferences (Business Wire)
Jun-12-24 08:00AM	Equillium to be included in the Russell Microcap Index (Business Wire)
Jun-05-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -19.08%
Jun-04-24 08:00AM	Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata (Business Wire) -27.89%
May-29-24 08:00AM	Equillium to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.48%
May-14-24 08:00AM	Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease (Business Wire)
May-09-24 10:56PM	EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.88% -15.00%
05:35PM	Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights (Business Wire)
May-07-24 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists (Business Wire)
Apr-03-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.88%
Apr-01-24 10:15AM	Equillium's lupus drug improves kidney biomarker, teeing up opt-in decision from Ono (FierceBiotech.com) -8.66%
08:00AM	Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis (Business Wire)
Mar-25-24 09:53PM	EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -13.48% -15.57%
05:10PM	Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights (Business Wire)
Mar-22-24 08:00AM	Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference (Business Wire)
Jan-29-24 04:07AM	15 Cash-Rich Penny Stocks Hedge Funds Are Buying (Insider Monkey)
Dec-21-23 09:52AM	Equillium swaps multi-cytokine inhibitor for oral option after underwhelming phase 2 data (FierceBiotech.com) -9.57%
08:00AM	Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease (Business Wire)
Nov-20-23 11:23AM	EQ Bank Card launches in Québec as Carte Banque EQ (PR Newswire)
Nov-13-23 09:00AM	Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology (Business Wire)
Nov-08-23 04:01PM	Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (Business Wire)
Nov-06-23 08:00AM	Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology (Business Wire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) -7.52%
Oct-19-23 08:00AM	Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology (Business Wire)
Oct-16-23 08:00AM	Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium (Business Wire) +6.66%
Oct-03-23 08:00AM	Equillium to Host Analyst & Investor Day (Business Wire)
Oct-02-23 08:00AM	Equillium to Present at the JonesTrading 2023 Healthcare Summit (Business Wire)
Sep-20-23 08:00AM	Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences (Business Wire)
Aug-30-23 08:00AM	Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference (Business Wire)
Aug-12-23 08:05AM	Equillium, Inc. (NASDAQ:EQ) Just Reported, And Analysts Assigned A US$6.06 Price Target (Simply Wall St.)
Aug-09-23 05:30PM	Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (Business Wire)
Aug-02-23 04:00PM	Equillium Announces $7.5 Million Share Repurchase Program (Business Wire)
Jun-01-23 08:00AM	Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences (Business Wire)
May-15-23 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists (Business Wire) +16.84%
May-11-23 05:25PM	Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Connelly Stephen	Officer	Jun 05 '26	Proposed Sale	2.94	30,975	91,070		Jun 05 05:07 PM
Zedelmayer Christine	Sr. Vice President and COO	Jun 05 '26	Option Exercise	0.79	14,584	11,448	77,170	Jun 05 04:42 PM
Zedelmayer Christine	Sr. Vice President and COO	Jun 05 '26	Sale	2.93	14,584	42,737	62,586	Jun 05 04:42 PM
Connelly Stephen	President and CSO	Jun 04 '26	Sale	3.16	200,000	632,760	793,000	Jun 05 04:42 PM
Connelly Stephen	President and CSO	Jun 05 '26	Sale	2.94	30,975	91,070	762,025	Jun 05 04:42 PM
Connelly Stephen	Officer	Jun 04 '26	Proposed Sale	3.16	200,000	632,760		Jun 04 05:30 PM
Tom Penny	Principal Accounting Officer	May 28 '26	Option Exercise	0.79	65,000	51,025	65,000	May 29 06:28 PM
Tom Penny	Principal Accounting Officer	May 28 '26	Sale	2.95	65,000	191,750	0	May 29 06:28 PM
Zedelmayer Christine	Sr. Vice President and COO	May 28 '26	Option Exercise	0.77	86,012	66,391	118,390	May 29 06:19 PM
Zedelmayer Christine	Sr. Vice President and COO	May 27 '26	Option Exercise	0.77	9,821	7,562	72,407	May 29 06:19 PM
Zedelmayer Christine	Sr. Vice President and COO	May 28 '26	Sale	2.80	86,012	240,693	62,586	May 29 06:19 PM
Zedelmayer Christine	Sr. Vice President and COO	May 27 '26	Sale	2.70	9,821	26,517	62,586	May 29 06:19 PM
Zedelmayer Christine	Officer	May 27 '26	Proposed Sale	2.63	65,625	172,593		May 27 04:14 PM
Zedelmayer Christine	Sr. Vice President and COO	Mar 13 '26	Option Exercise	0.79	120,312	94,445	182,898	Mar 16 06:53 PM
Zedelmayer Christine	Sr. Vice President and COO	Mar 13 '26	Sale	2.50	120,312	300,816	62,586	Mar 16 06:53 PM
Zedelmayer Christine	Officer	Mar 13 '26	Proposed Sale	2.40	120,312	288,748		Mar 13 04:08 PM
Zedelmayer Christine	Sr. Vice President and COO	Mar 09 '26	Option Exercise	0.79	152,361	119,603	243,805	Mar 11 08:11 PM
Zedelmayer Christine	Sr. Vice President and COO	Mar 09 '26	Sale	2.00	181,219	362,438	62,586	Mar 11 08:11 PM
Zedelmayer Christine	Officer	Mar 09 '26	Proposed Sale	1.77	181,219	320,757		Mar 09 04:07 PM
Zedelmayer Christine	Sr. Vice President and COO	Feb 19 '26	Option Exercise	0.76	185,937	141,750	300,819	Feb 23 12:52 PM
Zedelmayer Christine	Sr. Vice President and COO	Feb 19 '26	Sale	1.76	185,937	328,104	191,444	Feb 23 12:52 PM
Zedelmayer Christine	Officer	Feb 19 '26	Proposed Sale	1.70	185,937	316,092		Feb 19 04:03 PM
Tom Penny	Principal Accounting Officer	Jan 08 '26	Sale	1.29	6,533	8,428	0	Jan 09 05:37 PM
Tom Penny	Officer	Jan 08 '26	Proposed Sale	1.29	6,533	8,427		Jan 08 12:22 PM
Zedelmayer Christine	Sr. Vice President and COO	Dec 23 '25	Option Exercise	0.79	100,000	78,500	191,444	Dec 23 04:24 PM
Zedelmayer Christine	Sr. Vice President and COO	Dec 23 '25	Sale	1.50	100,000	150,000	91,444	Dec 23 04:24 PM
Zedelmayer Christine	Officer	Dec 23 '25	Proposed Sale	1.50	100,000	150,000		Dec 23 04:18 PM
Zedelmayer Christine	Sr. Vice President and COO	Dec 12 '25	Sale	1.34	23,804	31,897	103,344	Dec 15 05:39 PM
Zedelmayer Christine	Sr. Vice President and COO	Dec 15 '25	Sale	1.31	11,900	15,589	91,444	Dec 15 05:39 PM
Zedelmayer Christine	Officer	Dec 12 '25	Proposed Sale	1.34	23,804	31,897		Dec 12 04:01 PM
Zedelmayer Christine	Sr. Vice President and COO	Nov 25 '25	Sale	0.95	8,098	7,696	127,148	Nov 25 06:08 PM
Zedelmayer Christine	Officer	Nov 25 '25	Proposed Sale	0.92	8,098	7,428		Nov 25 02:43 PM

Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March 2017 and is headquartered in La Jolla, CA.

Co-FounderMr. Bruce Steel

Chief Scientific Officer & PresidentDr. Stephen Connelly Ph.D.

P.M.P.Ms. Christine Zedelmayer M.B.A.

Senior VP of Finance & Principal Accounting OfficerMs. Penny Tom CPA

Vice President of Investor Relations & Corporate CommunicationsMr. Michael Moore

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EQ

Equillium Inc

Upgrade your Finviz experience